Sandoz delivers 6% sales growth with Humira biosimilar leading the charge

Sandoz delivers 6% sales growth with Humira biosimilar leading the charge

Source: 
Fierce Pharma
snippet: 

In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab).